Apatinib, an antiangiogenesis agent targeting vascular endothelial growth factor receptor-2 (VEGFR-2), demonstrates satisfactory efficacy in advanced nonsmall cell lung cancer (NSCLC) patients.[5]. The gene discussed is KDR; the disease is non-small cell lung carcinoma.